痛风男性中别嘌醇与非布司他疗效与尿酸排泄分数的关系
研究纳入1547例起始别嘌醇和296例起始非布司他的痛风患者,评估尿酸排泄分数(FEUA)≤5.5%或>5.5%与剂量反应的关系。FEUA≤5.5%者别嘌醇每增加150mg血清尿酸降幅更大(-72.37 vs -65.96 μM,P=0.032),FEUA最低者氧嘌醇浓度更高(P=0.032),非布司他反应与FEUA无交互(P=0.13)。
要点
- FEUA≤5.5%的痛风男性对别嘌醇的降尿酸反应优于FEUA>5.5%者。
- FEUA最低者氧嘌醇浓度更高,可能因氧嘌醇肾脏排泄减少。
- 非布司他降尿酸反应与FEUA无显著交互作用(P=0.13)。
核心结论
- 别嘌醇在低FEUA患者中更有效,可能因氧嘌醇肾脏排泄减少。
- 数据提示氧嘌醇与尿酸的肾脏处理具有相似性。
研究设计与样本
- 数据来自1547例起始别嘌醇和296例起始非布司他的患者。
- 采用线性混合效应回归模型评估FEUA(≤5.5%或>5.5%)与剂量反应的关系,并校正BMI、eGFR和治疗剂量。
- 在181例子组中测量氧嘌醇浓度,采用多元线性回归模型评估FEUA与氧嘌醇浓度的关联,校正BMI、eGFR、别嘌醇剂量和血清尿酸水平。
主要发现
- 全人群FEUA中位数为4.0%(四分位1-3:3%-5.1%)。
- FEUA≤5.5%者别嘌醇每增加150mg血清尿酸变化为-72.37 μM(CI -74.81至-69.94),FEUA>5.5%者为-65.96 μM(CI -71.29至-60.62),P=0.032。
- FEUA最低者氧嘌醇浓度更高(P=0.032)。
- 非布司他反应与FEUA无交互作用(P=0.13)。
临床怎么用
- 原文未报告临床实践推荐。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Body mass index (BMI), glomerular filtration rate (GFR), and pretreatment urate levels have been reported to influence the urate-lowering response to allopurinol. We investigated whether the fractional excretion of uric acid (FEUA) also modulates this response and relates to oxypurinol concentrations. We further evaluated its potential influence on febuxostat, not as a direct comparison, but to determine whether the effect of FEUA was specific to allopurinol. METHODS: The data are from n = 1,547 and n = 296 patients starting allopurinol and febuxostat, respectively. The relationship between FEUA (≤5.5% or >5.5%) and the dose response to allopurinol or febuxostat was assessed by linear mixed-effects regression models on serum urate levels and adjusted for BMI, estimated GFR (eGFR), and treatment doses. Concentrations of oxypurinol were measured in a subgroup of patients (n = 181). A multiple linear regression model was used to assess the association between FEUA and oxypurinol concentrations, adjusted for BMI, eGFR, allopurinol dosage, and serum urate levels. RESULTS: The median FEUA in the whole population was 4.0% (quartile 1-3: 3%-5.1%). The changes in serum urate levels for each 150-mg increase in allopurinol in patients with FEUA ≤5.5% or >5.5% were -72.37 (confidence interval [CI] -74.81 to -69.94) μM and -65.96 (CI -71.29 to -60.62) μM, respectively (P = 0.032). We found higher oxypurinol concentrations in patients with the lowest FEUA (P = 0.032). However, we did not observe any interaction between the febuxostat response and FEUA (P = 0.13). CONCLUSION: Allopurinol is more effective in patients with low FEUA, probably because of the reduced renal excretion of oxypurinol. These data highlight the similarity between the renal handling of oxypurinol and urate.
引用
- Richette P, Walter-Petrich A, Nguyen QD, et al. Response to Allopurinol and Febuxostat According to the Fractional Excretion of Urate in Men With Gout. Arthritis Care Res (Hoboken). 2026. PMID: 41236172. doi:10.1002/acr.25695
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。